Product Description
Jiangsu Hengrui Medicine Co is developing shr-4640, an Oral URAT1 Inhibitor for Gout; a highly selective urate transporter 1 inhibitor. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04052932; https://pubmed.ncbi.nlm.nih.gov/33693494/)
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Hengrui Pharmaceutical
Company Location: Asia Pacific
Company Founding Year: 1970
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Gout
Phase 1: Healthy Volunteers|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05954169 |
SHR4640-111 | P1 |
Completed |
Kidney Diseases |
2024-07-01 |
2024-07-12 |
Primary Completion Date|Primary Endpoints |
|
NCT07362355 |
SHR4640-204 | P2 |
Recruiting |
Gout |
2027-07-01 |
50% |
2026-04-08 |
Primary Endpoints|Start Date|Treatments|Trial Status |
CTR20234227 |
CTR20234227 | P1 |
Completed |
Gout |
2024-02-16 |
2025-04-29 |
||
CTR20233979 |
CTR20233979 | P1 |
Completed |
Gout |
2024-01-13 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06168929 |
SHR4640-112 | P1 |
Completed |
Healthy Volunteers |
2024-01-13 |
2024-01-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06196580 |
SHR4640-113 | P1 |
Completed |
Gout |
2024-02-16 |
2024-03-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20232161 |
CTR20232161 | P1 |
Completed |
Healthy Volunteers |
2024-07-01 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/15/2021 |
News Article |
Hyperuricemia (Metabolic Disorder) Drugs In Development, 2021 Pipeline Landscape Report - ResearchAndMarkets.com |